Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + QL1101
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
toripalimab + QL1101 is an investigational combination therapy being evaluated for the treatment of pMMR/MSS refractory metastatic colorectal cancer. Toripalimab (JS001) is a humanized IgG4 monoclonal antibody developed by Shanghai Junshi Biosciences that targets the programmed death-1 (PD-1) receptor to restore T-cell anti-tumor activity. QL1101, developed by Qilu Pharmaceutical, is a biosimilar of bevacizumab that targets vascular endothelial growth factor (VEGF), thereby inhibiting tumor angiogenesis. This combination is being studied in a Phase 2 clinical trial sponsored by the Second Affiliated Hospital, School of Medicine, Zhejiang University, with the aim of overcoming the typical resistance of microsatellite stable (MSS) colorectal cancers to single-agent immune checkpoint inhibitors by modulating the tumor microenvironment through anti-angiogenic therapy.
- Brand names
- TuoyiLoqtorzi
- Other names
- toripalimab-Second Affiliated Hospital, School of Medicine, Zhejiang University-colorectal cancer (metastatic)Tripleitriumabtoripalimab + bevacizumab biosimilar
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on toripalimab + QL1101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + QL1101.